Stage T1-2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy

International Journal of Radiation Oncology Biology Physics

Volumn 37, Issue 5, 1997, Pages 1043-1052

  Kupelian, Patrick A ^a   Katcher, Jerald ^a   Levin, Howard S ^a   Klein, Eric A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Androgen suppression; Prognostic factors; Prostate specific antigen; Prostatectomy; Prostatic neoplasms; Radiotherapy

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT FAILURE;

ADULT; AGE FACTORS; AGED; DISEASE-FREE SURVIVAL; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SALVAGE THERAPY; SURVIVAL RATE;

EID: 0030955710     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(96)00590-1     Document Type: Article

References (25)

1. Ackerman, D.; Barry, J.; Wicklund, R.; Olson, N.; Lowe, B. Analysis of risk factors associated with prostate cancer extension to the surgical margins and pelvic node metastases at radical prostatectomy. J. Urol. 150:1845-1850; 1993.
2. Catalona, W.; Bigg, S. Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J. Urol. 143:538-544; 1990.
3. D'Amico, A.; Whittington, R.; Malkowicz, S.; Schultz, D.; Schnall, M.; Tomaszewski, J.; Wein, A. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J. Urol. 154:131-138; 1995.
4. Epstein, J. Evaluation of radical prostatectomy capsular margins of resection: The significance of margins designated as negative, closely approaching, and positive. Am. J. Surg. Pathol. 14:626-632; 1990.
5. Epstein, J.; Carmichael, M.; Partin, A.; Walsh, P. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of follow-up. J. Urol. 149:1478-1481; 1993.
6. Epstein, J.; Pizov, G.; Walsh, P. Correlation of pathologic findings with progression following radical prostatectomy. Cancer 71:3582-3593; 1993.
7. Frazier, H.; Robertson, J.; Humphrey, P.; Paulson, D. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J. Urol. 149:516-518; 1993.
8. Harris, E.; Albert, A. Survivorship analysis for clinical studies. New York: Marcel Dekker; 1991.
9. Kaplan, I.; Cox, R.; Bagshaw, M. Prostate specific antigen after external beam radiotherapy for prostate cancer: follow-up. J. Urol. 149:519-522; 1993.
10. Kupelian, P.; Katcher, J.; Levin, H.; Zippe, C.; Klein, E. Correlation of clinical and pathologic factors with rising PSA profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 48:249-260; 1996.
11. Kupelian, P.; Levin, H.; Zippe, C.; Klein, E. External beam radiotherapy versus radical prostatectomy for localized prostate cancer: A single institution experience. J. Urol. 155:556A; 1996.
12. Ohori, M.; Wheeler, T.; Kattan, M.; Goto, Y.; Scardino, P. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J. Urol. 154:1818-1824; 1995.
13. Partin, A.; Pound, C.; Clemens, J.; Epstein, J.; Walsh, P. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years, Urol. Clin. North Am. 20:713-725; 1993.
14. Partin, A.; Yoo, J.; Carter, H.; Pearson, J.; DW, C.; Epstein, J.; Walsh, P. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol. 150:110-114; 1993.
15. Paulson, D. Impact of radical prostatectomy in the management of clinically localized disease. J. Urol. 152:1826-1830; 1994.
16. Pisansky, T.; Cha, S.; Earle, J.; Durr, E.; Kozelsky, T.; Wieand, H.; Oesterling, J. Prostate-specific antigen as a pre-therapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J. Clin. Oncol. 11:2158-2166; 1993.
17. Ravery, V.; Delmas, V.; Boccon-Gibod, L.; Meulemans, A.; Dauge-Geffroy, M.; Toublanc, M.; Billebaud, T.; Boccon-Gibod, L. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology 44:371-376; 1994.
18. Ritter, M.; Messing, E.; Shanahan, T.; Potts, S.; Chappell, R.; Kinsella, T. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J. Clin. Oncol. 10:1208-1217; 1992.
19. Soloway, M.; Sharifi, R.; Wajsman, Z.; D. M.; Puras-Baez, A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J. Urol. 154:424-428; 1995.
20. Stamey, T.; Villers, A.; McNeal, J.; Link, P.; Freiha, F. Positive surgical margins at radical prostatectomy: importance of the apical dissection. J. Urol. 143:166-173; 1990.
21. Weldon, V.; Tavel, F.; Neuwirth, H.; Cohen, R. Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J. Urol. 151:1565-1569; 1994.
22. Zagars, G.; Pollack, A. Radiation Therapy for T1 and T2 prostate cancer: Prostatic-specific antigen and disease outcome. Urology 45:476-483; 1995.
23. Zagars, G.; von Eschenbach, A. Prognostic factors in prostate cancer: Prostate specific antigen: An important marker for prostate cancer treated by external beam radiotherapy. Cancer 72:538-548; 1993.
24. Zietman, A.; Coen, J.; Shipley, W.; Willett, C.; Efrid, J. Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate-specific antigen value as a predictor of treatment outcome. J. Urol. 151:640-645; 1994.
25. Zincke, H.; Oesterling, J.; Blute, M.; Bergstralh, E.; Myers, R.; Barrett, D. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol. 152:1850-1857; 1994.